The IQVIA Institute’s latest report identifies a biosimilar void. Despite their proven value, biosimilars are facing barriers at every turn. If nothing changes, patients and the healthcare system will pay the price.
Join Us October 27–29 for GRx+Biosims™ 2025
GRx+Biosims™ 2025 is the leading science, regulatory and policy event for the U.S. generic and biosimilar medicines industry. Access timely information from subject matter experts and U.S. regulatory professionals, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development. Register now to attend and stay on the cutting edge of our essential industry!
U.S. Generic & Biosimilar Medicines Savings Report
Representing 90% of prescriptions filled but only 12% of spending, generics and biosimilars are essential to America’s patients and the U.S. healthcare system. The 2025 U.S. Generic & Biosimilar Medicines Savings Report shows – savings will only continue to grow if policymakers and regulators prioritize alleviating the unique challenges impacting this essential industry.
Press Releases
What’s New
Approved Biosimilars in the U.S.
>90
Biosimilars Currently in Development
2.7B
Days of Patient Therapy with Biosimilars
Incremental Days of Biosimilar Therapy
